<DOC>
	<DOCNO>NCT02445183</DOCNO>
	<brief_summary>The COPDGene® / Lung Cancer Database Study nest case-control study . This study ancillary study COPDGene® Phase 1 Phase 2 . Lung cancer case , report COPDGene® subject since time COPDGene® study enrollment , retrospectively verify additional medical data collection pertain lung cancer . Additional 'control ' subject also identify verified 'no lung cancer control ' . Data previously collect COPDGene® Study , include QCT result clinical result ( medication use , rate acute exacerbation COPD , etc ) use variable analysis .</brief_summary>
	<brief_title>COPDGene/Lung Cancer Center Database</brief_title>
	<detailed_description>COPDGene® subject screen several mechanism enrollment Lung Cancer Database : 1 . The COPDGene® Phase 1 Longitudinal Follow-up Questionnaire . 2 . The COPDGene® Phase 2 Medical History Questionnaire Visit 1 3 . Medical Records Collection Mortality Adjudication Committee Potential case respond yes lung cancer contact phone study coordinator screen COPDGene® Lung Cancer Database . Medical record analyze determine patient 's cancer diagnosis , pathology , treatment . Information collect individual institution , de-identified , enter password-protected COPDGene® DCC lung cancer database , web-based interface . The survival data obtain review medical record Social Security Death Index conjunction COPDGene® mortality adjudication committee . For nested case-control study , control match subject COPDGene answer 'No ' longitudinal follow-up question `` diagnosed lung cancer '' per COPDGene protocol . Medical record regard patient 's cancer diagnosis , pathology treatment collect follow sign release medical information patient . The following information collect enter database . The survival data obtain review medical record Social Security Death Index . . Date diagnosis ii . Type specimen iii . Laterality iv . Lobe v. Record false positive ( use verify control ) b . Pathology Findings : i. Histology ii . Molecular Analysis , do . iii . Stage ( TNM classification ) iv . Histologic grade c. Treatment . Surgery ii . Radiation iii . Chemotherapy iv . Presentation Tumor Board d. Outcomes . Recurrence , Second primary cancer ii . Survival cancer diagnosis , Cause death Study coordinator site contact subject self-reported lung cancer identify lung cancer follow-up clinic visit complete lung cancer data form . The data collect subject de-identified recruiting site prior download COPDGene® DCC locate National Jewish Health . A lung cancer adjudication committee , include Drs . Carr Bowler , review case accuracy completeness .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Subjects must meet follow criterion 1 . Be enrol COPDGene® Phase 1 without enrollment Phase 2 newly diagnose , ( within time enrollment ) , nonsmall cell lung cancer ( NSCLC ) smallcell lung cancer ( SCLC ) . 2 . Documented GOLD stage 14 COPD history smoke COPD 3 . Signed HIPAA Research Authorization Release Protected Health Information form collect review medical record regard lung cancer diagnosis , treatment , outcome</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>